{"entity":{"id":"paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023","kind":"paper","name":"Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms","aka":[],"tldr":"In 232 Swedish early triple-negative cancers, half were PD-L1-positive by the atezolizumab test (SP142 IC 1%) but only 27% by the pembrolizumab threshold (22C3 CPS 10), and the two tests picked partly different patients.","summary":"PD-L1 by SP142 immune-cell score and 22C3 combined positive score was compared in 232 early-stage TNBC patients from the population-based SCAN-B cohort. Positivity was 50.9% for SP142 IC 1% or more, 27.2% for 22C3 CPS 10 or more, 53.9% for CPS 1 or more and 41.8% for 22C3 IC 1% or more. Concordance between SP142 IC-positive and the three 22C3 scores was 73.7% (kappa 0.48), 81.5% (0.63) and 86.6% (0.73). CD274 mRNA correlated with every scoring (Spearman 0.59 to 0.62). PD-L1 positivity and TILs were favourable prognostic factors in chemotherapy-treated patients, strongest for CPS 10 and distant relapse-free interval (HR 0.18), but PD-L1 was not independent of TILs.","asOf":"2026-09-24","links":[{"label":"Sigurjonsdottir et al., Breast Cancer Res 2023: SP142 versus 22C3 in 232 population-based early TNBCs (SCAN-B)","url":"https://doi.org/10.1186/s13058-023-01724-2"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/37817263/"}],"tags":[],"related":["pd-l1-ic-score","pd-l1-cps"],"cancers":["tnbc","tnbc-early"],"sections":[],"technologies":[],"targets":["pdl1"],"drugs":["ventana-pd-l1-sp142","dako-pd-l1-22c3-pharmdx"],"companies":[],"institutions":["lund-skane"],"pathways":[],"terms":["cps","tils","ihc"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["breast-cancer-research"],"dependsOn":[],"notes":[],"journal":"Breast Cancer Research","year":2023,"doi":"10.1186/s13058-023-01724-2","pmid":"37817263","authors":"Sigurjonsdottir G, De Marchi T, Ehinger A, et al.","paperType":"observational","findings":["SP142 IC 1% or more 50.9%; 22C3 CPS 10 or more 27.2%; CPS 1 or more 53.9%.","SP142 versus CPS 10 agreement weak (kappa 0.48).","PD-L1 was prognostic but not independent of tumour-infiltrating lymphocytes."],"whatItMeans":"This is the population-based prevalence for the two label thresholds in early TNBC, and it shows the KEYNOTE-355 CPS 10 gate would admit only about a quarter of unselected patients.","caveats":["Early-stage surgical specimens; the trials scored metastatic biopsies.","Single Swedish region."],"changedPractice":false,"participants":232},"route":"/key-papers/paper-sigurjonsdottir-sp142-22c3-tnbc-bcr-2023/","neighbours":{"biomarker":[{"id":"pd-l1-cps","kind":"biomarker","name":"PD-L1 CPS (combined positive score)","route":"/biomarkers/pd-l1-cps/"},{"id":"pd-l1-ic-score","kind":"biomarker","name":"PD-L1 IC score (immune-cell score, SP142)","route":"/biomarkers/pd-l1-ic-score/"}],"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"},{"id":"tnbc","kind":"cancer","name":"Triple-negative breast cancer (TNBC)","route":"/cancers/tnbc/"}],"target":[{"id":"pdl1","kind":"target","name":"PD-L1","route":"/targets/pdl1/"}],"drug":[{"id":"dako-pd-l1-22c3-pharmdx","kind":"drug","name":"PD-L1 IHC 22C3 pharmDx","route":"/drugs/dako-pd-l1-22c3-pharmdx/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"ventana-pd-l1-sp142","kind":"drug","name":"VENTANA PD-L1 (SP142) Assay","route":"/drugs/ventana-pd-l1-sp142/"}],"institution":[{"id":"lund-skane","kind":"institution","name":"Skåne University Hospital / Lund University Cancer Centre","route":"/institutions/lund-skane/"}],"term":[{"id":"cps","kind":"term","name":"Combined positive score (CPS)","route":"/terms/cps/"},{"id":"ihc","kind":"term","name":"Immunohistochemistry (IHC)","route":"/terms/ihc/"},{"id":"tils","kind":"term","name":"Tumour-infiltrating lymphocytes (TILs)","route":"/terms/tils/"}],"journal":[{"id":"breast-cancer-research","kind":"journal","name":"Breast cancer research","route":"/journals/breast-cancer-research/"}],"trial":[{"id":"keynote-355","kind":"trial","name":"KEYNOTE-355","route":"/trials/keynote-355/"}]}}